🟢 Inovio Pharmaceuticals is trading 5.9% up in pre-market after announcing an $80.4 million judgment

Inovio Pharmaceuticals is trading at $1.07 (+5.94%) in pre-market, with its $80,416,101 judgment announcement a possible catalyst. - On October 20, the company announced a judgment against VGXI and GeneOne; it cautioned that the defendants’ financial condition may hinder collection. - Hantavirus-related vaccine-stock enthusiasm was also reported as a possible, unconfirmed overnight factor; no confirmed connection to Inovio was established.